Creatinine News and Research RSS Feed - Creatinine News and Research

Urinary nerve growth factor shows diagnostic value

Urinary nerve growth factor shows diagnostic value

Urinary nerve growth factor could be a useful biomarker for the diagnosis of overactive bladder and a predictive biomarker to help guide treatment, Chinese researchers believe. [More]
Canada funds 22 inventive ideas for improving health in low-resource countries

Canada funds 22 inventive ideas for improving health in low-resource countries

Grand Challenges Canada, funded by the Government of Canada, today announced $2.4 million in seed funds shared between 22 projects from Canada and nine developing nations, to pursue inventive new ideas for improving health in low-resource countries. [More]
Inflammatory marker signals diabetic nephropathy development

Inflammatory marker signals diabetic nephropathy development

Measuring serum levels of high-sensitivity C-reactive protein could help to predict which patients with Type 2 diabetes will develop renal disease, research suggests. [More]
Lifestyle intervention shows kidney benefits in diabetic patients

Lifestyle intervention shows kidney benefits in diabetic patients

A lifestyle intervention focused on weight loss and increasing physical activity should be considered as additional treatment to prevent advanced kidney disease in overweight or obese people with Type 2 diabetes, say researchers. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Hypertension control may ward off renal damage in diabetics

Hypertension control may ward off renal damage in diabetics

Elevated blood pressure is associated with an increased risk of renal damage in patients with Type 2 diabetes, especially if they have poor glycaemic control, study findings suggest. [More]
Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

Randox Cystatin C facilitates early detection and treatment of chronic kidney disease

As a more sensitive maker of renal dysfunction Randox Cystatin C offers several advantages over traditional creatinine assays. [More]
Night-time BP variability improves vascular risk prediction

Night-time BP variability improves vascular risk prediction

Measuring night-time variability in the blood pressure of patients with hypertension may help to predict their risk of having a cardiovascular event, show data from an international study. [More]
Standard risk factors stratify already high-risk diabetic patients

Standard risk factors stratify already high-risk diabetic patients

Cardiovascular disease risk factors are associated with mortality even among patients with Type 2 diabetes who are already at high risk due to having high coronary artery calcified plaque, say researchers. [More]
Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

Acute kidney injury and chronic kidney disease are interconnected, say GW researchers

For more than 40 years, physicians have treated diminished kidney function as two distinct syndromes: acute kidney injury (AKI) and chronic kidney disease (CKD). However, recent epidemiologic and mechanistic studies suggest the two syndromes are not distinct entities, but interconnected. [More]
Study calls for improvements in physicians' inconsistent record of ordering lab tests

Study calls for improvements in physicians' inconsistent record of ordering lab tests

Why does one physician in a walk-in practice order laboratory monitoring tests for patients more often than a colleague working down the hallway? [More]
Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4). [More]
FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

FDA accepts Pharmacyclics' IMBRUVICA sNDA for review

Pharmacyclics, Inc. today announced that the U.S. Food and Drug Administration has accepted for filing its supplemental New Drug Application (sNDA) to support the review of IMBRUVICA (ibrutinib) in the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who have received at least one prior therapy for a full approval. [More]
Cardiac biomarkers aid microvascular risk prediction in diabetics

Cardiac biomarkers aid microvascular risk prediction in diabetics

Assessing cardiac biomarkers results in a moderate improvement in the ability to predict microvascular complications in patients with Type 2 diabetes, say researchers. [More]
New therapies for kidney disease can be developed by revising definition of kidney disease

New therapies for kidney disease can be developed by revising definition of kidney disease

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that new therapies for kidney disease could be developed more quickly by revising the definition of kidney disease progression used during clinical trials. [More]
Global risk assessment urged for hypertensive patients

Global risk assessment urged for hypertensive patients

Global risk assessment has a large impact on the risk stratification and therefore management of patients with hypertension, a study shows. [More]
FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

FDA approves Alexion’s Soliris drug for treatment of atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's supplemental Biologics License Application (sBLA) providing regular approval for Soliris® (eculizumab) for the treatment of adult and pediatric patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). [More]
Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals reports results from CTP-499 Phase 2 trial in patients with diabetic kidney disease

Concert Pharmaceuticals, Inc. today announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease. CTP-499, when used in addition to the standard of care, is being developed to delay the progression of these patients to end-stage renal failure, which requires dialysis or kidney transplantation. [More]
Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

Novel prediction model improves patient outcomes after paracetamol-induced acute liver failure

In the UK paracetamol toxicity is the most common cause of ALF and has a high mortality rate. It is estimated that 150 to 200 deaths and 15 to 20 LTs occur as a result of poisoning each year in England and Wales. [More]
Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens, NKF form new alliance to improve screening for kidney disease in high-risk individuals

Siemens Healthcare and the National Kidney Foundation (NKF) announced today a new strategic alliance focusing on education, awareness and screening for kidney disease in high-risk individuals. This important collaboration will leverage the latest testing recommendations from the NKF to improve detection among the 73 million Americans at risk for kidney disease. [More]